Order Article Reprints

Sanz-Álvarez M, Cristóbal I, Luque M, Santos A, Zazo S, Madoz-Gúrpide J, Caramés C, Chiang C-M, García-Foncillas J, Eroles P, et al. Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients. Cancers. 2021; 13(6):1246. https://doi.org/10.3390/cancers13061246

Sanz-Álvarez, Marta, Ion Cristóbal, Melani Luque, Andrea Santos, Sandra Zazo, Juan Madoz-Gúrpide, Cristina Caramés, Cheng-Ming Chiang, Jesús García-Foncillas, Pilar Eroles, and et al. 2021. "Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients" Cancers 13, no. 6: 1246. https://doi.org/10.3390/cancers13061246

Sanz-Álvarez, M., Cristóbal, I., Luque, M., Santos, A., Zazo, S., Madoz-Gúrpide, J., Caramés, C., Chiang, C.-M., García-Foncillas, J., Eroles, P., Albanell, J., & Rojo, F. (2021). Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients. Cancers, 13(6), 1246. https://doi.org/10.3390/cancers13061246